FindTrial
Sign In

The Vaccination Cohort Study on: 1. Immunologic Protection after Vaccination of Immune-compromised Patients 2. Assessment of the Infection Rate after International Travel

The Vaccination Cohort Study on: 1. Immunologic Protection after Vaccination of Immune-compromised Patients 2. Assessment of the Infection Rate after International Travel - The Vaccination Cohort Study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38641
Enrollment
200
Registered
2014-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Travellers vaccination

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: All individuals, irrespective of age, sex and underlying illness visiting the Erasmus MC *vaccination and travel clinic* requiring travel related, medically indicated or voluntary vaccination(s)

Exclusion criteria

Exclusion criteria: No informed consent

Design outcomes

Primary

MeasureTime frame
The antibody titer after vaccination of immune compromised patients compared to immunocompetent patients and the incidence of infectious diseases during travel—

Secondary

MeasureTime frame
1a The capability of naïve memory B cells to generate an antibody response after live, conjugated and polysaccharide vaccine dose increase in case of non-responders 1b Dendritic cell function and antigen presentation properties 1c CD8+ cytotoxic properties 1d Waning effects of vaccines by the presence of a prolonged (i.e. after 6 months) qualitative antibody response by detecting high affinitive IgG antibodies in serum as well as B-cell reactivation properties—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)